Gilead Sciences stock holds near highs as CEO share sale and HIV growth shape outlook

Gilead Sciences (ISIN US3755581036) stock is trading near the top of its recent range after the company reported quarterly revenue of 7.80 billion USD with double-digit growth and its CEO executed a programmed share sale in early September 2026, according to MarketBeat data as of September 2, 2026.

CEO share sale draws attention but leaves large stake

According to a detailed insider trading overview from MarketBeat, Gilead Sciences CEO Daniel Patrick O'Day sold a total of 15,000 shares of Gilead common stock on September 1, 2026 under a pre arranged Rule 10b5-1 trading plan.

The filing shows that the shares were sold at an average price of 148.64 USD per share, resulting in proceeds of about 2.23 million USD, while O'Day retained 577,133 shares after the transaction, a reduction of 2.53 percent in his position according to the same report.

Recent earnings show double digit revenue growth

Gilead Sciences recently posted quarterly revenue of 7.80 billion USD, beating the 7.40 billion USD consensus estimate cited in the MarketBeat analysis and marking a 10.6 percent increase compared with the same quarter a year earlier.

In the same earnings release summary, the company reported adjusted earnings per share that came in ahead of analyst expectations, while generally accepted accounting principles EPS for the quarter was negative at minus 6.75 USD, leaving the reported net margin at minus 10.64 percent and return on equity at minus 2.11 percent, a combination that underscores how restructuring charges and one time items weigh on profitability despite top line growth.

Beyond the latest quarter, MarketBeat notes that analysts expect Gilead Sciences to post a small full year loss of about 0.47 USD per share for the current fiscal year, before returning to positive EPS growth in later years as recently approved and pipeline medicines ramp up.

Analyst view and valuation context

The same MarketBeat overview highlights that Gilead Sciences currently carries a consensus rating described as Moderate Buy, with an average analyst price target of 158.04 USD per share, implying about 5.4 percent upside compared with the 149.92 USD level cited as a recent Nasdaq opening price in early September 2026.

Another valuation snapshot discussed in a Simply Wall St narrative compares an estimated fair value of 128.38 USD per share with a 149.92 USD share price, framing Gilead Sciences as about 16.8 percent above that fair value yardstick and signaling that the stock is trading at a premium to certain discounted cash flow based models.

Analyst commentary also points to the role of newly approved medicines such as the HIV treatment Bixlenvo and oncology combinations in sharpening the medium term growth story, with Zacks and other houses revising their longer term EPS estimates higher for fiscal 2027, according to the MarketBeat summary.

HIV portfolio expansion and product focus

Gilead Sciences has historically generated a large portion of its revenue from HIV therapies, and that segment continues to grow as new products enter the market and pre exposure prophylaxis gains wider adoption.

As reported by Pharmavoice on September 2, 2026, Gilead’s HIV prevention franchise reached 1.0 billion USD in quarterly pre exposure prophylaxis sales in the second quarter of 2026, with the once daily Yeztugo tablet contributing 232 million USD in that period and phase 3 trial data showing that at least 99.9 percent of participants receiving Yeztugo remained HIV negative.

The same article notes that the United States Food and Drug Administration accepted Gilead’s application for a once weekly Yeztugo formulation, setting a February 2, 2027 Prescription Drug User Fee Act date, which gives investors a concrete regulatory milestone to watch as the company seeks to further differentiate its HIV portfolio.

Stock performance and DACH trading reference

On the German Tradegate platform, Gilead Sciences shares trade under the ticker GIS, and an Ad Hoc News summary drawing on Zonebourse data mentions a Tradegate price of 129.36 EUR as of September 1, 2026 at 22:02:47, representing a 2.68 percent gain on the day and placing the stock near the upper end of its recent euro range for DACH investors.

In United States trading, MarketBeat cites a recent Gilead Sciences share price of 149.61 USD during a Nasdaq session with about 4.92 million shares exchanged, alongside a 52 week range of 108.46 USD to 157.29 USD and a market capitalization of 185.51 billion USD, underscoring that the current price is closer to the high end of the annual band than to the low.

Viewed against this backdrop and the 158.04 USD average target, Gilead Sciences stock is priced within a narrow corridor below the consensus target but above some fair value estimates, so for investors the key question becomes whether double digit revenue growth and pipeline catalysts such as Yeztugo and Bixlenvo can sustain this elevated trading range.

Key commercial products and diversification

Gilead Sciences, Inc., headquartered in Foster City, California, develops and commercializes medicines spanning HIV and viral hepatitis, COVID 19, oncology and inflammatory diseases.

According to the product overview on Yahoo Finance, its HIV portfolio includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera and Eviplera, Stribild, Sunlencs and Atripla, while other antiviral offerings such as Veklury for COVID 19 and Epclusa, Harvoni, Vemlidy and Viread for hepatitis strengthen the company’s antiviral base.

In oncology and cell therapy, Gilead markets Yescarta and Tecartus for hematologic malignancies and Trodelvy for certain solid tumors, and has complemented these assets with licensing and collaboration agreements with partners including Arcus Biosciences, Merus and Arcellx to broaden its pipeline in immuno oncology and trispecific antibody approaches.

Closing view on Gilead Sciences stock

Based on recent data compiled by MarketBeat, Gilead Sciences stock recently traded at about 149.61 USD on Nasdaq with a 52 week high of 157.29 USD, while German investors saw a price of 129.36 EUR on Tradegate as of September 1, 2026, placing the share near yearly highs on both sides of the Atlantic.